Cover Image
市場調查報告書

中國的Aripiprazole市場分析

Investigation Report on China Aripiprazole Market, 2009-2018

出版商 China Research and Intelligence 商品編碼 297274
出版日期 內容資訊 英文 40 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
中國的Aripiprazole市場分析 Investigation Report on China Aripiprazole Market, 2009-2018
出版日期: 2014年03月06日 內容資訊: 英文 40 Pages
簡介

Aripiprazole(商品名「Abilify」),是大塚製藥開發的新世代抗精神病藥。2002年在美國首次發售,用於精神分裂症臨床治療。Aripiprazole銷售全世界,2012年的全球整體銷售額大約是42億美元。精神分裂症的長期性臨床治療顯示Aripiprazole的整體安全性。

本報告提供中國的Aripiprazole市場相關調查分析、主要廠商的市場佔有率、醫院市場上的銷售價格、主要製造商簡介、醫院市場上的市場佔有率(各劑型)、市場預測等,為您概述為以下內容。

第1章 Aripiprazole的相關概念

  • 適應
  • 全球市場銷售情形

第2章 中國的Aripiprazole的市場概要

  • 專利狀況
  • 主要製造商
  • 市場規模

第3章 中國的Aripiprazole的銷售額分析

  • 整體銷售額
  • 銷售額:各地區

第4章 中國的Aripiprazole的主要廠商的市場佔有率分析

  • 市場佔有率:各銷售額
  • 市場佔有率:各銷售量

第5章 中國的Aripiprazole(各劑型)的市場規模分析

  • 各市場佔有率:銷售額、劑型
  • 各市場佔有率:銷售量、劑型

第6章 中國的醫院市場上Aripiprazole的標準價格(各企業)

  • Zhejiang Otsuka Pharmaceutical Co., Ltd.
  • Kang Hong Pharmaceutical Co., Ltd.
  • Shanghai Zhongxi Pharmaceutical Co., Ltd.

第7章 中國的Aripiprazole市場上主要製造商分析

  • Zhejiang Otsuka Pharmaceutical Co., Ltd.
  • Kang Hong Pharmaceutical Co., Ltd.
  • Shanghai Zhongxi Pharmaceutical Co., Ltd.

第8章 中國的Aripiprazole市場預測

  • 中國的精神分裂症的發病率趨勢
  • 學名藥狀況
  • 市場規模的預測
  • 競爭格局的預測

圖表

目錄
Product Code: 1403129

Schizophrenia is a common mental disorder. Data shows that mental illness has exceeded cardiovascular system, respiratory diseases and malignant tumors and turns into the heaviest social burden. Statistics shows that by the end of 2013 there have been over 10 million schizophrenia patients in China, and the number is still increasing year after year.

Schizophrenia is a chronic persistent disease with recurrent deterioration. Only a small number of patients can be healed. It requires long-term treatment and close coordination between doctors, families and patients. Medication is the main method to treat schizophrenia while others such as psychotherapy are merely adjuvant treatment that cannot replace medication.

Aripiprazole is a new generation of antipsychotic drugs developed by Otsuka Pharmaceutical Co., Ltd. with the trade name "Abilify". It was firstly launched in the U.S. at the fourth quarter of 2002 and used in schizophrenia clinical treatment. Aripiprazole's sales revenue in the U.S. was USD 500 million in 2003 and USD 1 billion in 2006, and it grew by 50% in 2006. Abilify is sold worldwide by Otsuka and BMS. Its global sales revenue was about USD 4.2 billion in 2012. Evidence shows that aripiprazole is overall safe for long-term clinical treatment of schizophrenia.

In China, Zhejiang Otsuka Pharmaceutical Co., Ltd. spent 3 years developing the medication and finally received new drug certificate and production approval on December 20, 2006. It was approved to the market by the CFDA.

Chinese pharmaceutical manufacturers began to apply for aripiprazole generic drug production in 2003. As of early 2014 there are 4 approved manufacturers in China.

According to CRI's investigation on Chinese sample hospital market, the CAGR of sales revenue of aripiprazole was about 40% from 2007 to 2012, which was higher than the overall growth rate of antipsychotic drug market in China.

Otsuka and Lundbeck announced in November 2013 that the marketing authorization application (MAA) of the long-acting version of the antipsychotic drug Abilify Maintena (aripiprazole) was approved by the European Commission (EC) as a monthly intramuscular injection dosage form drug to treat adult schizophrenia patients who take aripiprazole orally. Similar drugs are expected to appear on Chinese market very soon.

Due to economic development and lifestyle changes, incidence of schizophrenia in China is predicted to increase in the next few years. Since people's income increases and health care improves, demand of antipsychotic drugs in China will continue to grow as well as the market size of aripiprazole.

Through this report, the readers can acquire the following information:

  • Market Share of Aripiprazole Produced by Different Enterprises in China Hospital Market
  • Sales Price of Aripiprazole in China Hospital Market
  • Major Aripiprazole Enterprises in China
  • Share of Aripiprazole in Different Dosage Forms in China Hospital Market
  • Prospect of China Aripiprazole Market

The Following Enterprises and People Are Recommended to Purchase This Report:

  • Antipsychotic APIs and Finished Product Manufacturers
  • Investors Focusing on China Antipsychotic Drug Market

Table of Contents

1. Relevant Concepts of Aripiprazole

  • 1.1. Development Process and Indication
  • 1.2. Sales Status on the Global Market

2. Market Overview of Aripiprazole in China, 2009-2013

  • 2.1. Patent Status and "Bolar Exception"
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Investigation on Sales Value of Aripiprazole in China, 2009-2013

  • 3.1. Total Sales Value
  • 3.2. Sales Value by Region

4. Investigation on Market Share of Major Aripiprazole Manufacturers in China, 2009-2013

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Investigation on Market Size of Aripiprazole by Dosage Form in China, 2009-2013

  • 5.1. Market Share by Sales Value and Dosage Form
  • 5.2. Market Share by Sales Volume and Dosage Form

6. Reference Price of Aripiprazole Produced by Different Enterprises in China Hospital Market

  • 6.1. Zhejiang Otsuka Pharmaceutical Co., Ltd.
  • 6.2. Kang Hong Pharmaceutical Co., Ltd.
  • 6.3. Shanghai Zhongxi Pharmaceutical Co., Ltd.

7. Analysis on Major Aripiprazole Manufacturers in China, 2009-2014

  • 7.1. Zhejiang Otsuka Pharmaceutical Co., Ltd.
  • 7.2. Kang Hong Pharmaceutical Co., Ltd.
  • 7.3. Shanghai Zhongxi Pharmaceutical Co., Ltd.

8. Prospect of China Aripiprazole Market, 2014-2018

  • 8.1. Trend of Schizophrenia Incidence in China
  • 8.2. Research Status of Generic Drug
  • 8.3. Forecast on Market Size
  • 8.4. Forecast on Competition Pattern

Selected Charts

  • Chart Aripiprazole Products Approved to Market in China by 2014
  • Chart Sales Value of Aripiprazole in Global Market, 2009-2013
  • Chart Sales Value of Aripiprazole in China Hospital Market, 2009-2013
  • Chart Sales Value of Aripiprazole by Region in China, 2009-2013
  • Chart Market Share of Aripiprazole Enterprises by Sales Value in China, 2009-2013
  • Chart Price of Aripiprazole Produced by Zhejiang Otsuka Pharmaceutical Co., Ltd. in China Hospital Market, 2014
  • Chart Price of Aripiprazole Produced by Kang Hong Pharmaceutical Co., Ltd. in China Hospital Market, 2014
  • Chart Forecast on Market Size of Hospital-use Atorvastatin in China, 2014-2018
Back to Top